Ethic Inc. Has $7.60 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ethic Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,668 shares of the biopharmaceutical company’s stock after purchasing an additional 4,509 shares during the period. Ethic Inc.’s holdings in Regeneron Pharmaceuticals were worth $7,599,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 3.6 %

Regeneron Pharmaceuticals stock opened at $527.78 on Friday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $57.70 billion, a P/E ratio of 13.79, a P/E/G ratio of 2.34 and a beta of 0.43. The firm has a 50 day moving average price of $613.08 and a 200-day moving average price of $696.77. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the company posted $9.55 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating on the stock in a report on Wednesday, April 30th. Guggenheim dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. UBS Group decreased their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research report on Friday, April 25th. Finally, Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.